

## Special Issue

# Epstein-Barr Virus-Associated Cancers: From Pathogenesis to Treatment (2nd Edition)

### Message from the Guest Editor

After almost 60 years of research on Epstein–Barr virus (EBV), its precise role in oncogenesis and clinical management of EBV-associated cancers remain unresolved. Much is still unknown about the natural history of EBV infection and its interaction with risk factors to promote cancer development. This Special Issue aims to assess the current understanding of EBV's role in virus-associated lymphomas and carcinomas and how this knowledge impacts diagnosis and treatment. We welcome original research articles and reviews on topics including: (i) EBV's role in various cancers, including latent and lytic proteins; (ii) interaction with co-factors in oncogenesis; (iii) EBV's impact on the tumor microenvironment; (iv) EBV as a biomarker in diagnosis and prognosis; (v) current and future treatments, including immunotherapy and targeting EBV proteins; and (vi) prophylactic and therapeutic vaccination approaches.

---

### Guest Editor

Prof. Dr. Kwok-Wai Lo

Department of Anatomical and Cellular Pathology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China

---

### Deadline for manuscript submissions

31 July 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/226086](https://mdpi.com/si/226086)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)